Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment?
Authors:
- Nathalie Costedoat-ChalumeauNCNathalie Costedoat-Chalumeau
- 1 January 2010
- journal article
- editorial
- Published by Elsevier in Joint Bone Spine
- Vol. 77 (1) , 4-5
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohortAnnals of the Rheumatic Diseases, 2009
- Hydroxychloroquine and Risk of Diabetes in Patients With Rheumatoid ArthritisJAMA, 2007
- Antimalarials may influence the risk of malignancy in systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2007
- Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosusLupus, 2007
- Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritisLupus, 2006
- Nonmyeloablative Hematopoietic Stem Cell Transplantation for Systemic Lupus ErythematosusJAMA, 2006
- Combined Oral Contraceptives in Women with Systemic Lupus ErythematosusNew England Journal of Medicine, 2005
- Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosusLupus, 2005
- Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 1997
- A Randomized Study of the Effect of Withdrawing Hydroxychloroquine Sulfate in Systemic Lupus ErythematosusNew England Journal of Medicine, 1991